Dublin, Aug. 16, 2017 (GLOBE NEWSWIRE) — The “R&D and Business Tracker for Bispecific Antibodies” newsletter has been added to Research and Markets’ offering.
This information service about Bispecific Antibodies delivers 12 monthly update reports in pdf format by e-mail straight to your desk and provides online access to the author’s R&D database for the subject field of the service during the one-year subscription period. Credentials to access the online database will be sent by e-mail within 24 hours after purchase.
This product consists of:
– 12 monthly update reports in pdf format delivered by e-mail
– online access to Bispecific Antibody R&D database during the 1-year subscription period
The R&D and Business Tracker for Bispecific Antibodies covers;
– T-Cell redirecting bispecific cancer antibodies
– NK cell redirecting bispecific cancer antibodies
– Bispecific immuno-oncology antibodies
– Bispecific tumor antigens targeted cancer antibodies
– Bispecific antibodies for inflammatory & autoimmune diseases
– Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases
The monthly update report about Bispecific Antibodies contains:
R&D and Technology Tracker
– Pipeline changes
– Regulatory news
– Technology validations
Business Tracker for:
– Company updates
– Collaboration
– Licensing
– Merger & acquisitions
– Financing
Clinical Trial Tracker
Scientific Publication Tracker
Featured Bispecific Antibody or Technology Profile
Featured Company Profile
Featured Target or Technology Pipeline
For more information about this newsletter visit https://www.researchandmarkets.com/research/6mq6rw/randd_and
CONTACT: CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Immune Disorders Drugs, Oncology Drugs